Yuandong Biological Announcement: It plans to invest 245 million yuan to participate in the big health industry fund

On February 16, Yuandong Biological announced that in order to better implement the strategic development plan of Yuandong Biological, the company plans to cooperate with Suzhou Venture Capital, Suzhou Angel Venture Capital Guiding Fund Management Co.
, Ltd.
, Suzhou High-tech Venture Capital Group Co.
, Ltd.
, Suzhou Medical Device Industry Development Co.
, Ltd.
and Mr.
Yang Hao jointly initiated the establishment of Suzhou Shouzheng Phase I Venture Capital Partnership (Limited Partnership) (hereinafter referred to as "the Fund")
.
The size of the fund is 500 million yuan, of which the company subscribes and contributes 245 million yuan with its own funds
.
The fund focuses on the big health industry, focusing on the field of biomedicine, focusing on innovative drugs, biological drugs, and other large health fields such as medical devices, precision medicine, medicine/medical technology services or technology platforms
.
Yuandong Biology stated in the announcement that the company uses the industry experience, resource advantages and management platform of professional investment institutions to obtain corresponding industry resources and reserves of potential direct bidding; at the same time, it combines the management experience and risk control of fund managers and general partners.
The system helps the company grasp the investment opportunities of early projects, reduce investment risks, obtain investment returns, and improve the company's profitability
.
The basic information of the partners shows that the general partner Suzhou Venture Capital is located in Room 905, Shishan Science and Technology Museum, No.
105 Dengwei Road, Suzhou High-tech Zone, with a registered capital of 7.
5 million yuan.
The company was established on June 18, 2021
.
The business scope includes general projects: venture capital (limited to investment in unlisted companies); private equity funds engaged in equity investment, investment management, asset management and other activities (the business activities must be completed after registration with the China Securities Investment Fund Industry Association) (except (Except for the projects subject to approval according to law, it can carry out business activities independently according to the law with the business license)
.
For this cooperative investment, Yuandong Bio said that it is based on the needs of the company's strategic development plan.
The fund's investment field is the big health industry, focusing on innovative drugs and biological drugs
.
The purpose of this cooperation with professional investment institutions is to learn from the professional investment experience of the partners, cultivate and reserve projects and technical resources for the company that are synergistic with the company's strategy, so as to further expand the company's industrial layout and enhance the company's competition in the field of biomedicine.
strength
.
At the same time, the company emphasized that this investment is an investment decision made on the premise of ensuring the normal development of the company's main business, and will not cause financial pressure on the company's existing business development, and will not affect the normal operation of the company's production and operation activities
.
With the help of the investment management experience and risk control system of professional investment institutions, this investment can provide guarantee for the healthy and sustainable development of the company, and there is no situation that damages the interests of the listed company and all shareholders
.
In addition, the Fund is not included in the company's consolidated financial statements and will not have a significant impact on the company's operating performance in 2022
.
There is also uncertainty about the impact on the company's future financial condition and results of operations
.
According to the data, Yuandong Bio is a biopharmaceutical company driven by research and development, integrating the entire industrial chain of chemical raw materials, high-end chemical drugs, and biological drugs
.
Relying on its own R&D technology platform, the company has intensively deployed in the field of anesthesia and analgesia, while taking into account the rapid development of large-variety market fields such as diabetes, cardiovascular, and anti-tumor, and accelerating the research and development and industrialization of small molecular entities and biological drugs
.
According to the 2021 third quarter report, the company's main income was 773 million yuan, a year-on-year increase of 14.
97%; the net profit attributable to the parent was 186 million yuan, a year-on-year increase of 49.
03%
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.